Attralus has filed a notice of an exempt offering of securities to raise $55,999,931.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Attralus is raising up to $55,999,931.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Mark Timney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Attralus
Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.
To learn more about Attralus, visit http://www.attralus.com/
Contact:
Mark Timney, Chief Executive Officer
415-410-3268
https://www.linkedin.com/in/mark-timney-052a08136/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.